Mizuho raises BridgeBio Pharma stock price target to $110 on Attruby

BBIO is transitioning from a hype-driven biotech to a real commercial asset, which changes the valuation framework: the market will start paying for launch durability and margin conversion rather than just pipeline optionality. The near-term winner is likely the equity story itself, but the sponsor secondary is an important technical overhang; when a large holder sells into strength, upside often pauses until the new supply is absorbed. That means the stock can still re-rate over 1-3 months if sell-side numbers keep moving higher, but the first move may be choppy rather than linear.

The competitive read-through is more important than the headline. The setback for IONS/AZN removes a credible future threat, which should extend BBIO’s runway and reduce the probability of an early price-war in the ATTR franchise; that supports share capture and pricing power for at least the next 2-4 quarters. Longer term, the real question is whether BBIO can turn early demand into a repeatable prescribing habit without payer friction or slowdown in treatment-naive starts. If the next earnings print shows deceleration or gross-to-net pressure, the market will likely compress the multiple quickly because the story has moved from science risk to execution risk.

Contrarian view: consensus may be underestimating how much of the first leg is already in the price. The Street is extrapolating an unusually clean launch curve and a more benign competitive backdrop; both are fragile. A move above recent highs is plausible, but unless the company proves sustained script velocity into the Commercial Day and post-secondary period, the stock is vulnerable to a "show-me" reset. For GILD, the read-through is milder: investors may favor large-cap biotech with visible execution, but this is more a factor rotation tailwind than a direct earnings impact.